CannabisNewsWire
Editorial Coverage: Leveraging ever-expanding scientific
evidence of the therapeutic efficacy of CBD (cannabidiol),
specialty biotechnology companies are creating novel new
formulations of the chemical compound to capitalize on the titanic
growth expected in the cannabis-derived pharmaceutical and
nutraceutical markets.
Cannabinoids have been used for medicinal purposes for
millennia, but it wasn’t until the discovery of the human
endocannabinoid system in the 1990s that scientists began to
comprehend their importance in healing and homeostasis. The
identification of human cannabinoid receptors opened the floodgates
to new cannabis-based medications. Increased understanding of the
endocannabinoid system sparked further scientific research and led
to the realization that cannabinoids impact a much wider range of
physiological functions than previously realized. Specialty
biotechnology companies soon blossomed and now these companies
research and develop wide-ranging novel new drug candidates to
improve and extend patients’ lives, creating unique medicines to
treat multiple maladies and answer unmet medical needs. These
pioneering biotech companies are committed to developing
cannabis-based pharmaceuticals and nutraceuticals delivered with
unparalleled safety and new-found efficacy. At the vanguard of this
surge in cannabinoid therapeutics, Earth Science Tech, Inc.
(OTC: ETST) (ETST
Profile) has taken another major step in its mission
to become a global leader in the research, development and sale of
hemp-derived, CBD-based pharmaceuticals,
nutraceuticals and dietary supplements. The company’s recent
decision to uplist on the OTCQB exchange will likely increase
visibility and liquidity, and its comprehensive strategy of
scientific development combined with robust retail creates a unique
opportunity in the burgeoning medical cannabis markets. Other
companies vying for position in these lucrative markets include
CV Sciences, Inc. (OTC: CVSI), Axim
Biotechnologies, Inc. (OTC: AXIM), GB Sciences,
Inc. (OTC: GBLX) and Vitality Biopharma (OTC:
VBIO).
To view an infographic of this editorial, click here.
Massive Markets
Little wonder that cannabis biotech companies are operating at
full throttle. The global medical
marijuana market is anticipated to exceed $55 billion by 2025
and, to meet increasing consumer demand, hemp-based nutraceuticals
are rapidly gaining significant traction in a global
nutraceuticals market projected to surpass $319 billion within
the next five years. These eye-popping projections bode well for
diversified cannabis biotech companies. CBD pharmaceuticals and
nutraceuticals are the fastest growing sectors in the legal
cannabis markets and the sector itself is among the fastest growing
in all the markets. With multiple clinical research studies
suggesting that CBD based pharmaceuticals and nutraceuticals have
the potential to treat arthritis, MS, chronic pain, depression,
epilepsy and a myriad of other illnesses and maladies, the
prodigious market projections might even be underestimated.
Another Milestone
Seizing on the immense market opportunity and validating
efficacy through scientific processes, Earth Science
Tech, Inc. (OTC: ETST) is intent on becoming a global
leader in the research, development and sale of hemp-derived,
CBD-based pharmaceuticals, nutraceuticals and dietary supplements.
The company has racked up a succession of achievements since
inception and its latest announcement establishes another milestone
in its march toward global recognition. The company just issued a
press release confirming that the U.S.
Securities and Exchange Commission (SEC) approved the company’s
Form 10 Registration Statement and Earth Sciences has officially
up-listed to an OTCQB fully reporting company as of Sept. 10. The
higher standards of the OTCQB markets provide a strong baseline for
transparency, as well as the technology and regulations to enhance
both access to information and trading experiences for investors.
“Historically, up-listing to the OTCQB and being fully reporting
has resulted in greater liquidity and awareness. We are committed
to the higher level of corporate and financial disclosures required
as an OTCQB fully reporting company, demonstrating our commitment
to our loyal shareholders,” stated ETST’s President, Director and
Chairman Nickolas S. Tabraue.
Eyes on the Prize
Grounded in science, ETST still understands that sales are
essential for continued success. Earth Science aggressively markets
and sells the highest-available quality and purity full spectrum
hemp oil containing CBD. The company’s products are formulated
using superior supercritical CO2 cold liquid extraction, where the
cannabinoids are kept at the rawest state possible to maintain
essential therapeutic properties. Earth Science’s CBD products are
marketed through multiple venues including a national group of
independent distributors representing grocery and convenience
stores, a national association of buying groups and trade
organizations reaching up to
90,000 retail outlets, health food giant Karmavore Superfoods,
international supplement distributor Forzagen, innumerable vape and
e-liquid smoke shops, and online.
The company has four distinct, wholly owned subsidiaries:
- Cannabis Therapeutics, Inc., (CTI) is developing an array of
cannabinoid-based pharmaceuticals and nutraceuticals.
- Kannabidioid, Inc., manufactures and distributes
vapes/e-liquids and gummy edibles to vape and smoke shops.
- Earth Science Pharmaceutical, Inc., (ESP) manufactures low-cost
medical devices and vaccines for protection against
sexually-transmitted infections.
- Earth Science Foundation, Inc., a nonprofit organization formed
to accept grants and donations to conduct further studies and help
donate CBD products to those in need.
Cannabis Therapeutics is deeply invested in research and
development to explore and harness the medicinal power of
cannabidiol. Over 113 cannabinoids have been isolated from the
cannabis plant, many obscure and only in trace amounts, but CBD,
for which Cannabis Therapeutics has a provisional application
patent, is the most promising of all. CTI’s mission is to develop
proprietary cannabinoid-based nutraceuticals and pharmaceutical
products using Earth Science Tech’s existing cannabis CBD patent
and IP, as well as expected future technologies.
The company recently updated its report on research progress on two new cannabinoid-based
pharmaceutical drugs, which are unique CBD formulated products – a
neuron protector and a breast protector. Earlier studies by DV
Biologics, a leading biological company, confirmed ETST high-grade
hemp CBD oil deterred the formation of reactive oxygen species and
cell death in human brain cells in vitro and may serve as a
neuroprotectant to mitigate neurodegenerative disorders such as
Alzheimer's and Parkinson's. With strong initial evidence that CBD
contains anti-breast cancer properties, Earth Sciences also
launched the development of proprietary prophylactic therapies to
prevent breast cancer, and a treatment to help women with
aggressive breast cancer. The company is very bullish on these CBD
formulas.
The R&D work in progress at the prestigious laboratory,
Centre De Développement Bioalimentaire Du Québec (CDBQ), has been
exceptionally promising. CDBQ is highly experienced and able to
utilize the most effective and economical solutions to develop
products with the best efficacy and price-to-quality-to-market
ratios. CDBQ is meticulously finalizing formulations that will
include natural protective agents to assure long shelf life of the
CBD formula.
The third CBD formula is a revolutionary superfood with unique
organoleptic properties never seen on the market. Formulated from a
mix of hemp oil and other vegetal oils, and enriched with a highly
potent antioxidant, this product is designed to improve antioxidant
ingestion. Earth Science developed this novel formula in
collaboration with experts that successfully developed multiple
products for some of the largest players in the food industry.
Not a One-trick Pony
Earth Science’s up-listing announcement is only the latest in a
succession of successful advancements the company has made since
its genesis. Last year’s
achievements verify that. In addition to talented and
experienced leadership, the company’s success lies in the broad
diversification of products, joint ventures, IPs and initiatives.
Beyond the company’s multiple CBD-based initiatives and ventures,
Earth Science’s medical device subsidiary Earth Science
Pharmaceutical is making significant strides in the development of
low-cost, noninvasive diagnostic tools, medical devices, testing
processes and vaccines for sexually transmitted infections and/or
diseases. The company’s first medical device, MSN-2, is a home kit
designed for the detection of STIs, such as chlamydia, from a
self-obtained gynecological specimen. ESP is working to develop and
bring to market medical devices and vaccines that meet the specific
needs of women.
Others Vying for Position
CV Sciences, Inc. (OTC: CVSI) focuses on the
drug development, marketing and sale of products containing
cannabidiol as the active pharmaceutical ingredient, and is engaged
in the sale of CBD as well. The company operates two distinct
business segments: a drug development division focused on
developing and commercializing novel therapeutics utilizing
synthetic CBD; and a consumer product division centered in the
manufacturing, marketing and sale of plant-based CBD products to a
range of market sectors.
Axim Biotechnologies, Inc. (OTC: AXIM)
researches, develops and produces cannabis-based pharmaceutical,
nutraceutical and cosmetic products. The company has several
products developed or in developmental stage for the treatment
and/or prevention of multiple conditions and symptoms. Axim’s
flagship products include a CBD-based, controlled-release chewing
gum, another gum containing 50 mg of CBD undergoing clinical trials
in patients with irritable bowel syndrome, and a combination
CBD/tetrahydrocannabinol (THC) gum that will undergo clinical
trials for the treatment of pain and spasticity associated with
MS.
GB Sciences, Inc. (OTC: GBLX) is a diverse
cannabis company focused on standardized cultivation and production
methods, as well as biopharmaceutical research and development. The
company’s goal is to create safe, standardized,
pharmaceutical-grade cannabinoid therapies that target a variety of
medical conditions. Company growth strategy is two-pronged —
biomedical research for the development of cannabis-based therapies
and the recreational market for cannabis in Nevada.
Vitality Biopharma (OTC: VBIO) is focused on
the use of cannabinoids for the treatment of serious neurological
and inflammatory disorders. The company has developed cannabinoid
prodrugs, known as cannabosides, which upon ingestion may enable
selective delivery of THC and CBD to the gastrointestinal tract.
Vitality has filed intellectual property applications and is
seeking global patent protection for prodrugs of THC, CB, and CBDV,
as well as for its proprietary prodrug biosynthesis platform
utilizing enzymatic glycosylation.
The Takeaway
As the list of curative applications continues to grow, there’s
no longer any doubt about the therapeutic efficacy of cannabidiol.
Employing that same certitude for impending CBD market growth has
the potential to create a profit bonanza in strategically
positioned portfolios.
For more information on Earth Science Tech, visit Earth Science
Tech, Inc. (OTC: ETST)
About CannabisNewsWire
CannabisNewsWire (CNW) is an information service that provides
(1) access to our news aggregation and syndication servers, (2)
CannabisNewsBreaks that summarize
corporate news and information, (3) enhanced press release
services, (4) social media distribution and optimization services,
and (5) a full array of corporate communication solutions. As a
multifaceted financial news and content distribution company with
an extensive team of contributing journalists and writers, CNW is
uniquely positioned to best serve private and public companies that
desire to reach a wide audience of investors, consumers,
journalists and the general public. CNW has an ever-growing
distribution network of more than 5,000 key syndication outlets
across the country. By cutting through the overload of information
in today’s market, CNW brings its clients unparalleled visibility,
recognition and brand awareness. CNW is where news, content and
information converge.
Receive Text Alerts
from CannabisNewsWire: Text "Cannabis" to
21000
For more information please visit https://www.CannabisNewsWire.com and
or https://CannabisNewsWire.News
Please see full terms of use and disclaimers on the
CannabisNewsWire website applicable to all content provided by CNW,
wherever published or re-published: http://CNW.fm/Disclaimer
CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net
DISCLAIMER: CannabisNewsWire (CNW) is the source of the Article
and content set forth above. References to any issuer other than
the profiled issuer are intended solely to identify industry
participants and do not constitute an endorsement of any issuer and
do not constitute a comparison to the profiled issuer. The
commentary, views and opinions expressed in this release by CNW are
solely those of CNW. Readers of this Article and content agree that
they cannot and will not seek to hold liable CNW for any investment
decisions by their readers or subscribers. CNW is a news
dissemination and financial marketing solutions provider and is NOT
registered broker-dealers/analysts/investment advisers, hold no
investment licenses and may NOT sell, offer to sell or offer to buy
any security.
The Article and content related to the profiled company
represent the personal and subjective views of the Author, and are
subject to change at any time without notice. The information
provided in the Article and the content has been obtained from
sources which the Author believes to be reliable. However, the
Author has not independently verified or otherwise investigated all
such information. None of the Author, CNW, or any of their
respective affiliates, guarantee the accuracy or completeness of
any such information. This Article and content are not, and should
not be regarded as investment advice or as a recommendation
regarding any particular security or course of action; readers are
strongly urged to speak with their own investment advisor and
review all of the profiled issuer’s filings made with the
Securities and Exchange Commission before making any investment
decisions and should understand the risks associated with an
investment in the profiled issuer’s securities, including, but not
limited to, the complete loss of your investment.
CNW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains “forward-looking statements” within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E the Securities Exchange Act of 1934, as amended and
such forward-looking statements are made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995. “Forward-looking statements” describe future expectations,
plans, results, or strategies and are generally preceded by words
such as “may”, “future”, “plan” or “planned”, “will” or “should”,
“expected,” “anticipates”, “draft”, “eventually” or “projected”.
You are cautioned that such statements are subject to a multitude
of risks and uncertainties that could cause future circumstances,
events, or results to differ materially from those projected in the
forward-looking statements, including the risks that actual results
may differ materially from those projected in the forward-looking
statements as a result of various factors, and other risks
identified in a company’s annual report on Form 10-K or 10-KSB and
other filings made by such company with the Securities and Exchange
Commission. You should consider these factors in evaluating the
forward-looking statements included herein, and not place undue
reliance on such statements. The forward-looking statements in this
release are made as of the date hereof and CNW undertakes no
obligation to update such statements.
Source:
CannabisNewsWire
Contact:
CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net
GB Sciences (CE) (USOTC:GBLX)
Gráfico Histórico do Ativo
De Fev 2025 até Mar 2025
GB Sciences (CE) (USOTC:GBLX)
Gráfico Histórico do Ativo
De Mar 2024 até Mar 2025
